Shopping Cart
Remove All
Your shopping cart is currently empty
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $579 | - | In Stock | |
| 5 mg | $1,580 | - | In Stock | |
| 10 mg | $2,530 | - | In Stock | |
| 25 mg | $3,750 | - | In Stock | |
| 50 mg | $4,960 | - | In Stock |
| Description | Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling. |
| Synonyms | PR1283233, PR 1283233, ABT-165, ABT165 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 1791420-09-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.